{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T03:43:46Z","timestamp":1784259826356,"version":"3.55.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T00:00:00Z","timestamp":1731974400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T00:00:00Z","timestamp":1731974400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Beijing Natural Science Foundation of China","award":["7232288"],"award-info":[{"award-number":["7232288"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-80236-1","type":"journal-article","created":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T07:30:35Z","timestamp":1732001435000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Pharmacovigilance study of famciclovir in the Food and Drug administration adverse event reporting system database"],"prefix":"10.1038","volume":"14","author":[{"given":"Runan","family":"Fang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,19]]},"reference":[{"issue":"6","key":"80236_CR1","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1007\/s00105-022-04992-9","volume":"73","author":"RN Werner","year":"2022","unstructured":"Werner, R. N. & Ghoreschi, K. Herpes zoster-prevention, diagnosis, and treatment. Hautarzt 73(6), 442\u2013451. https:\/\/doi.org\/10.1007\/s00105-022-04992-9 (2022).","journal-title":"Hautarzt"},{"issue":"9","key":"80236_CR2","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1097\/00002030-200006160-00019","volume":"14","author":"B Romanowski","year":"2000","unstructured":"Romanowski, B. et al. Efficacy and safety of famciclovir for treating mucocutaneous herpes simplex infection in HIV-infected individuals. Collaborative Famciclovir HIV Study Group. AIDS 14(9), 1211\u20131217. https:\/\/doi.org\/10.1097\/00002030-200006160-00019 (2000).","journal-title":"AIDS"},{"issue":"9","key":"80236_CR3","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1177\/106002809603000913","volume":"30","author":"AD Luber","year":"1996","unstructured":"Luber, A. D. & Flaherty, J. F. Jr. Famciclovir for treatment of herpesvirus infections. Ann. Pharmacother 30(9), 978\u2013985. https:\/\/doi.org\/10.1177\/106002809603000913 (1996).","journal-title":"Ann. Pharmacother"},{"issue":"4","key":"80236_CR4","doi-asserted-by":"publisher","first-page":"337","DOI":"10.36076\/ppj.2023.26.337","volume":"26","author":"Y Liu","year":"2023","unstructured":"Liu, Y. et al. A Network Meta-Analysis of Randomized clinical trials to assess the efficacy and safety of Antiviral agents for Immunocompetent patients with herpes Zoster-Associated Pain. Pain Physician 26(4), 337\u2013346 (2023).","journal-title":"Pain Physician"},{"issue":"12","key":"80236_CR5","doi-asserted-by":"publisher","first-page":"2904","DOI":"10.7860\/JCDR\/2013\/7884.3670","volume":"7","author":"MG Gopal","year":"2013","unstructured":"Gopal, M. G., Shannoma, Kumar, B. C. S., A S N, M. R. & Manjunath, N. C. A comparative study to evaluate the efficacy and safety of acyclovir and famciclovir in the management of herpes zoster. J. Clin. Diagn. Res. 7(12), 2904\u20132907. https:\/\/doi.org\/10.7860\/JCDR\/2013\/7884.3670 (2013).","journal-title":"J. Clin. Diagn. Res."},{"issue":"2","key":"80236_CR6","doi-asserted-by":"publisher","first-page":"89","DOI":"10.7326\/0003-4819-123-2-199507150-00002","volume":"123","author":"S Tyring","year":"1995","unstructured":"Tyring, S. et al. Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia. A randomized, double-blind, placebo-controlled trial. Collaborative Famciclovir Herpes Zoster Study Group. Ann. Intern. Med. 123(2), 89\u201396. https:\/\/doi.org\/10.7326\/0003-4819-123-2-199507150-00002 (1995).","journal-title":"Ann. Intern. Med."},{"issue":"2","key":"80236_CR7","doi-asserted-by":"publisher","first-page":"CD006866","DOI":"10.1002\/14651858.CD006866.pub3","volume":"2014","author":"N Chen","year":"2014","unstructured":"Chen, N. et al. Antiviral treatment for preventing postherpetic neuralgia. Cochrane Database Syst. Rev. 2014(2), CD006866. https:\/\/doi.org\/10.1002\/14651858.CD006866.pub3 (2014).","journal-title":"Cochrane Database Syst. Rev."},{"issue":"10","key":"80236_CR8","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1007\/978-3-319-44348-5_23","volume":"96","author":"A Saguil","year":"2017","unstructured":"Saguil, A., Kane, S., Mercado, M. & Lauters, R. Herpes zoster and postherpetic neuralgia: Prevention and Management. Am. Fam Physician 96(10), 656\u2013663. https:\/\/doi.org\/10.1007\/978-3-319-44348-5_23 (2017).","journal-title":"Am. Fam Physician"},{"issue":"3","key":"80236_CR9","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1007\/s00415-021-10487-9","volume":"269","author":"J Cao","year":"2022","unstructured":"Cao, J., Zhang, X. & Wang, Z. Effectiveness comparisons of antiviral treatments for Bell palsy: a systematic review and network meta-analysis. J. Neurol. 269(3), 1353\u20131367. https:\/\/doi.org\/10.1007\/s00415-021-10487-9 (2022).","journal-title":"J. Neurol."},{"issue":"40","key":"80236_CR10","doi-asserted-by":"publisher","first-page":"3192","DOI":"10.3760\/cma.j.cn112137-20220603-01237","volume":"102","author":"YX Deng","year":"2022","unstructured":"Deng, Y. X., Hu, J. & Li, H. M. Efficacy and safety of different doses of antiviral agents in the treatment of herpes zoster: a meta-analysis. Zhonghua Yi Xue Za Zhi 102(40), 3192\u20133200. https:\/\/doi.org\/10.3760\/cma.j.cn112137-20220603-01237 (2022).","journal-title":"Zhonghua Yi Xue Za Zhi"},{"issue":"1","key":"80236_CR11","doi-asserted-by":"publisher","first-page":"20601","DOI":"10.1038\/s41598-022-23726-4","volume":"12","author":"M Guo","year":"2022","unstructured":"Guo, M., Shu, Y., Chen, G., Li, J. & Li, F. A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for niraparib. Sci. Rep. 12(1), 20601. https:\/\/doi.org\/10.1038\/s41598-022-23726-4 (2022).","journal-title":"Sci. Rep."},{"key":"80236_CR12","unstructured":"Jiang, M. et al. Extracting and standardizing medication information in clinical text - the MedEx-UIMA system. AMIA Jt Summits Transl Sci Proc. ;2014:37\u201342. (2014)."},{"issue":"1","key":"80236_CR13","doi-asserted-by":"publisher","first-page":"7659","DOI":"10.1038\/s41598-024-58460-6","volume":"14","author":"Y Jiang","year":"2024","unstructured":"Jiang, Y., Lu, R., Zhou, Q., Shen, Y. & Zhu, H. Analysis of post-market adverse events of istradefylline: a real-world study base on FAERS database. Sci. Rep. 14(1), 7659. https:\/\/doi.org\/10.1038\/s41598-024-58460-6 (2024).","journal-title":"Sci. Rep."},{"key":"80236_CR14","doi-asserted-by":"publisher","first-page":"1194545","DOI":"10.3389\/fphar.2023.1194545","volume":"14","author":"Y Zhang","year":"2023","unstructured":"Zhang, Y., Ran, L., Liang, Y., Zhang, Y. & An, Z. Safety analysis of pemigatinib leveraging the US Food and Drug administration adverse event reporting system. Front. Pharmacol. 14, 1194545. https:\/\/doi.org\/10.3389\/fphar.2023.1194545 (2023).","journal-title":"Front. Pharmacol."},{"key":"80236_CR15","doi-asserted-by":"publisher","unstructured":"Tang, S., Wu, Z., Xu, L., Wen, Q. & Zhang, X. Adverse reaction signals mining and hemorrhagic signals comparison of ticagrelor and clopidogrel: A pharmacovigilance study based on FAERS. Front. Pharmacol. 2022 Oct. 313, 970066. https:\/\/doi.org\/10.3389\/fphar.2022.970066.","DOI":"10.3389\/fphar.2022.970066"},{"key":"80236_CR16","doi-asserted-by":"publisher","unstructured":"Park, G., Jung, H., Heo, S. J. & Jung, I. Comparison of Data Mining Methods for the Signal Detection of Adverse Drug Events with a Hierarchical Structure in Postmarketing Surveillance. Life (Basel). ;10(8):138. Published 2020 Aug 5. doi: (2020). https:\/\/doi.org\/10.3390\/life10080138","DOI":"10.3390\/life10080138"},{"key":"80236_CR17","doi-asserted-by":"publisher","first-page":"1320458","DOI":"10.3389\/fphar.2023.1320458","volume":"14","author":"F Zou","year":"2023","unstructured":"Zou, F. et al. A real-world pharmacovigilance study of mepolizumab in the FDA adverse event reporting system (FAERS) database. Front. Pharmacol. 14, 1320458. https:\/\/doi.org\/10.3389\/fphar.2023.1320458 (2023).","journal-title":"Front. Pharmacol."},{"issue":"34","key":"80236_CR18","doi-asserted-by":"publisher","first-page":"e213","DOI":"10.3346\/jkms.2018.33.e213","volume":"33","author":"HS Kim","year":"2018","unstructured":"Kim, H. S., Lee, S. & Kim, J. H. Real-world evidence versus Randomized Controlled Trial: Clinical Research based on Electronic Medical records. J. Korean Med. Sci. 33(34), e213. https:\/\/doi.org\/10.3346\/jkms.2018.33.e213 (2018).","journal-title":"J. Korean Med. Sci."},{"key":"80236_CR19","doi-asserted-by":"publisher","unstructured":"Van Oorschot, D. et al. A systematic literature review of herpes zoster incidence worldwide. Hum. Vaccin Immunother 17(6), 1714\u20131732. https:\/\/doi.org\/10.1080\/21645515.2020.1847582 (2021).","DOI":"10.1080\/21645515.2020.1847582"},{"issue":"1","key":"80236_CR20","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s40121-023-00902","volume":"13","author":"E S\u00f6dergren","year":"2024","unstructured":"S\u00f6dergren, E. et al. Incidence and Burden of Herpes Zoster in Sweden: a Regional Population-based Register Study. Infect. Dis. Ther. 13(1), 121\u2013140. https:\/\/doi.org\/10.1007\/s40121-023-00902 (2024).","journal-title":"Infect. Dis. Ther."},{"issue":"5","key":"80236_CR21","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1053\/j.ajkd.2012.12.008","volume":"61","author":"NN Lam","year":"2013","unstructured":"Lam, N. N. et al. Risk of acute kidney injury from oral acyclovir: a population-based study. Am. J. Kidney Dis. 61(5), 723\u2013729. https:\/\/doi.org\/10.1053\/j.ajkd.2012.12.008 (2013).","journal-title":"Am. J. Kidney Dis."},{"key":"80236_CR22","doi-asserted-by":"publisher","unstructured":"Gales, B. J. & Gales, M. A. Confusion and bradykinesia associated with famciclovir therapy for herpes zoster. Am J Health Syst Pharm. ;53(12):1454, 1456. doi: (1996). https:\/\/doi.org\/10.1093\/ajhp\/53.12.1454","DOI":"10.1093\/ajhp\/53.12.1454"},{"issue":"5","key":"80236_CR23","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1128\/AAC.01054-08","volume":"53","author":"X S\u00e1ez-Llorens","year":"2009","unstructured":"S\u00e1ez-Llorens, X. et al. Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection. Antimicrob. Agents Chemother. 53(5), 1912\u20131920. https:\/\/doi.org\/10.1128\/AAC.01054-08 (2009).","journal-title":"Antimicrob. Agents Chemother."},{"issue":"2\u20133","key":"80236_CR24","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/0166-3542(95)00941-8","volume":"29","author":"R Cirelli","year":"1996","unstructured":"Cirelli, R., Herne, K., McCrary, M., Lee, P. & Tyring, S. K. Famciclovir: review of clinical efficacy and safety. Antiviral Res. 29(2\u20133), 141\u2013151. https:\/\/doi.org\/10.1016\/0166-3542(95)00941-8 (1996).","journal-title":"Antiviral Res."},{"key":"80236_CR25","doi-asserted-by":"publisher","unstructured":"Li, Q. et al. Antiviral treatment for preventing postherpetic neuralgia. Cochrane Database Syst. Rev. (2), CD006866. https:\/\/doi.org\/10.1002\/14651858.CD006866.pub2 (2009).","DOI":"10.1002\/14651858.CD006866.pub2"},{"issue":"1","key":"80236_CR26","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1086\/498521","volume":"42","author":"FY Aoki","year":"2006","unstructured":"Aoki, F. Y. et al. Single-day, patient-initiated famciclovir therapy for recurrent genital herpes: a randomized, double-blind, placebo-controlled trial. Clin. Infect. Dis. 42(1), 8\u201313. https:\/\/doi.org\/10.1086\/498521 (2006).","journal-title":"Clin. Infect. Dis."},{"issue":"4","key":"80236_CR27","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1517\/14740338.2010.485189","volume":"9","author":"S Mubareka","year":"2010","unstructured":"Mubareka, S., Leung, V., Aoki, F. Y. & Vinh, D. C. Famciclovir: a focus on efficacy and safety. Expert Opin. Drug Saf. 9(4), 643\u2013658. https:\/\/doi.org\/10.1517\/14740338.2010.485189 (2010).","journal-title":"Expert Opin. Drug Saf."},{"issue":"6","key":"80236_CR28","doi-asserted-by":"publisher","first-page":"bbab347","DOI":"10.1093\/bib\/bbab347","volume":"22","author":"Y Noguchi","year":"2021","unstructured":"Noguchi, Y., Tachi, T. & Teramachi, H. Detection algorithms and attentive points of safety signal using spontaneous reporting systems as a clinical data source. Brief. Bioinform 22(6), bbab347. https:\/\/doi.org\/10.1093\/bib\/bbab347 (2021).","journal-title":"Brief. Bioinform"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-80236-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-80236-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-80236-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T12:05:42Z","timestamp":1732277142000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-80236-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,19]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["80236"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-80236-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4300885\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,19]]},"assertion":[{"value":"21 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"28637"}}